Table_1_Therapeutic efficacy of optimal pulse technology in the treatment of chalazions.DOC

IntroductionTo evaluate the efficacy of optimized pulse technology in treating chalazia.MethodsProspective before-after study. All patients received two sessions of optimal pulse technology (OPT) with an interval of 1 week. The first visit was before treatment and the patients underwent 2 treatment sessions with a 1-week interval. The non-invasive tear breakup time (NIBUT), corneal fluorescein staining (CFS) score, Schirmer’s test I without anesthesia, conjunctival hyperemia, and meibomian gland area were compared before and after treatment, and the related factors of curative effect were analyzed.Results23 patients (23 eyes) with chalazia were included. All patients received two sessions of OPT treatment at 1-week intervals. Following the first OPT treatment, a reduction in the chalazion size was observed in 17 patients (73.91%). One patient was completely cured, and 1 patient had an increase in the diameter of the chalazion. The meibomian gland area increased significantly compared to before treatment (p = 0.023). Compared with baseline, the conjunctival congestion and ST decreased, NIBUT increased, and there was no statistical difference. After the second treatment, the chalazion size decreased in 21 cases, and 3 patients were cured. A significant increase in the meibomian gland area compared with the baseline area (p < 0.001). Additionally, conjunctival congestion decreased significantly. After two sessions, the Schirmer test exhibited a decrease, and NIBUT increased, although these changes did not reach statistical significance. The curative effect was unrelated to sex, age, first onset, single disease, and other factors.ConclusionAfter treatment, the diameter of chalazions was reduced in 91.3% of the patients, and the area of the meibomian gland was significantly increased compared with that before treatment, which suggested that 2 OPT treatments at an interval of 1 week can improve the signs of adult patients in the non-acute infectious stage with chalazia.

为评估优化脉冲技术在治疗睑板腺囊肿中的有效性，本研究采用前瞻性前后对照研究方法。所有患者均接受了两次优化脉冲技术（OPT）治疗，两次治疗间隔为一周。首次访问为治疗前，患者进行了两次治疗，治疗间隔为一周。在治疗前后，对比了非侵入性泪膜破裂时间（NIBUT）、角膜荧光素染色（CFS）评分、无麻醉的Schirmer试验I、结膜充血以及睑板腺面积等指标，并分析了疗效的相关因素。结果显示，纳入了23名患有睑板腺囊肿的患者（23只眼睛）。所有患者均接受了两次间隔为一周的OPT治疗。在首次OPT治疗后，17名患者（73.91%）观察到睑板腺囊肿大小的减少。1名患者完全治愈，1名患者的睑板腺囊肿直径有所增加。与治疗前相比，睑板腺面积显著增加（p = 0.023）。与基线相比，结膜充血和ST减少，NIBUT增加，但无统计学差异。第二次治疗后，21个病例的睑板腺囊肿大小减少，3名患者被治愈。与基线面积相比，睑板腺面积显著增加（p < 0.001）。此外，结膜充血显著减少。两次治疗后，Schirmer试验显示减少，NIBUT增加，但这些变化未达到统计学上的显著性。疗效与性别、年龄、首次发作、单病种和其他因素无关。结论：治疗后，91.3%的患者睑板腺囊肿直径减小，与治疗前相比，睑板腺面积显著增加，这表明在一周间隔下进行两次OPT治疗可以改善非急性感染期成人患者的睑板腺囊肿症状。